Effect of age on the pharmacokinetics of fimasartan (BR-A-657)

Expert Opinion on Drug Metabolism and Toxicology

Volumn 7, Issue 11, 2011, Pages 1337-1344

  Lee, Hae Won ^a   Lim, Mi Sun ^a,b   Seong, Sook Jin ^a,b   Lee, Joomi ^a,b   Park, Jeonghyeon ^a,b   Seo, Jeong Ju ^a,b   Cho, Joo Youn ^c   Yu, Kyung Sang ^c   Yoon, Young Ran ^a,b  

^a Kyungpook National University   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

Author keywords

Age; Angiotensin II receptor antagonist; Fimasartan; Pharmacokinetics

Indexed keywords

CREATINE KINASE; FIMASARTAN;

ADULT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CREATINE KINASE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DISTRIBUTION VOLUME; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MASS SPECTROMETRY; NORMAL HUMAN; SIDE EFFECT; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE;

ADULT; AGE FACTORS; AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; AREA UNDER CURVE; BIPHENYL COMPOUNDS; HALF-LIFE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PYRIMIDINES; TABLETS; TETRAZOLES; YOUNG ADULT;

EID: 80054760390     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2011.618835     Document Type: Article

References (22)

1. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-23 (Pubitemid 40138015)
2. Chobanian AV, Bakris GL, Black HR, et al. the National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42:1206-52 (Pubitemid 37553153)
3. Smith DHG. Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension. Drugs 2008;68:1207-25 (Pubitemid 351822111)
4. Unger T. The role of the rennin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 2002;89(Suppl):3A-10A (Pubitemid 34143240)
5. Sica DA, Gehr TWB, Ghosh S. Clinical pharmacokinetics of losartan. Clin Pharmacokinet 2005;44:797-814 (Pubitemid 41126929)
6. Hernandez-Hernandez R, Sosa-Canche B, Velasco M, et al. Angiotensin II receptor antagonists role in arterial hypertension. J Hum Hypertens 2002;16(Suppl 1):S93-9 (Pubitemid 34441144)
7. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60
8. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8
9. Lane A, Engmann E, Bryson S, et al. Single dose pharmacokinetics (PK) and pharmacodynamics (PD) of BR-A-657, an angiotensin II (AII) antagonist. Clin Pharmacol Ther 2005;77:P59-9
10. Tenero DM, Martin DE, Miller AK, et al. Effect of age and gender on the pharmacokinetics of eprosartan. Br J Clin Pharmacol 1998;46:267-70 (Pubitemid 28404841)
11. Hubner R, Hogemann AM, Sunzel M, Riddell JG. Pharmacokinetics of candersartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. J Hum Hypertens 1997;11:S19-25 (Pubitemid 27464501)
12. Sioufi A, Marfil F, Jaouen A, et al. The effect of age on the pharmacokinetics of valsartan. Biopharm Drug Dispos 1998;19:237-44 (Pubitemid 28218418)
13. Herrlinger C, Klotz U. Drug metabolism and drug interactions in the elderly. Best Pract Res Clin Gastroenterol 2001;15:897-918 (Pubitemid 34110600)
14. Abernethy DR. Drug therapy in the elderly. In: Atkinson AJ Jr, Abernethy DR, Daniels CE, Dedrick RL, Markey SP. editors. Principles of clinical pharmacology. 2nd edition. Elsevier, Inc; San Diego: 2007. p. 375-88
15. Thomas GN, Chan P, Tomlinson B. The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension. Drugs Aging 2006;23:131-55
16. Hammerlein A, Derendorf H, Lowenthal DT. Pharmacokinetic and pharmacodynamic changes in the elderly. Clinical implications. Clin Pharmacokinet 1998;35:49-64 (Pubitemid 28318962)
17. Benet LZ, Hoener B. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 2002;71:115-21 (Pubitemid 34271114)
18. Davies NM, Takemoto JK, Brocks DR, Yanez JA. Multiple peaking phenomena in pharmacokinetic disposition. Clin Pharmacokinet 2010;49:351-77
19. Koepsell H, Lips K, Volk C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 2007;24:1227-51 (Pubitemid 46876495)
20. Belmin J, Levy BI, Michel J-B. Changes in the rennin-angiotensin- aldosterone axis in later life. Drugs Aging 1994;5:391-400 (Pubitemid 2157457)
21. Low PA. Prevalence of orthostatic hypotension. Clin Auton Res 2008;18(Suppl 1):8-13 (Pubitemid 351667197)
22. Turgut F, Balogun RA, Abdel-Rahman EM. Renin-angiotensin-aldosterone system blockade effects on the kindey in the elderly: benefits and limitations. Clin J Am Soc Nephrol 2010;5:1330-9